Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Melanoma 250Carcinoma, Non-Small-Cell Lung 86Carcinoma, Renal Cell 62Neoplasm Metastasis 53Neoplasms 51Prostatic Neoplasms 35Lung Neoplasms 32Uveal Melanoma 29Pancreatic Neoplasms 28Carcinoma, Hepatocellular 25Brain Neoplasms 24Colorectal Neoplasms 23Sarcoma 22Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 18Small Cell Lung Carcinoma 18Kidney Neoplasms 18Skin Neoplasms 17Diabetes Mellitus, Insulin-Dependent, 12 17Carcinoma, Transitional Cell 17Ovarian Neoplasms 15Urinary Bladder Neoplasms 14Triple Negative Breast Neoplasms 14Mesothelioma 13Glioblastoma 13Uterine Cervical Neoplasms 12Recurrence 12Multiple Myeloma 11Lymphoma 11Clear-cell metastatic renal cell carcinoma 11

Interventions

afamelanotide 2Specimen Handling 1Restraint, Physical 1Nivolumab 1Longitudinal Studies 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xeroderma Pigmentosum × Ipilimumab × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡